Our Proprietary Platform

Skyhawk's integrated platform combines AI-driven discovery with a unique understanding of RNA biology to identify and develop transformative small molecule medicines.

The Patient Need

26% of human proteins are presently considered to be disease-related; however, only 3% of human proteins are currently druggable using traditional protein-targeting methods. Skyhawk's RNA-targeted platform opens the door to the other 23% — proteins whose disease-causing RNA can be modulated with small molecules where the protein itself cannot be directly targeted.

26% of human proteins are disease-related
3% are druggable by conventional methods
23% newly accessible via RNA-targeting

SKYSTAR®

SKYSTAR® is Skyhawk's proprietary target assessment system, designed to screen more than 700 targets for pharmaceutical partners and internal programs. It integrates bioinformatic, structural, and computational biology data to rapidly identify and validate the best RNA targets for drug discovery.

  • ✓ Screens 700+ RNA targets for internal and partner programs
  • ✓ Integrates bioinformatic, structural, and computational biology data
  • ✓ Identifies high-confidence targets for small molecule modulation
  • ✓ Federally registered trademark of Skyhawk Therapeutics
SKYSTAR®

SKYLIBRARY™

SKYLIBRARY™ is Skyhawk's unique, custom-built and rapidly expanding library of RNA-targeting compounds. Designed from the ground up to interact with RNA rather than protein, SKYLIBRARY™ provides the chemical diversity needed to explore novel RNA-targeted drug candidates across therapeutic areas.

  • ✓ Purpose-built RNA-targeting compound collection
  • ✓ Rapidly expanding with novel chemical scaffolds
  • ✓ Optimized for RNA structural interactions
  • ✓ Foundation for all Skyhawk discovery programs
SKYLIBRARY™

SKYSEQ™

SKYSEQ™ is Skyhawk's proprietary multiplex screening system, capable of simultaneously testing dozens of high-value RNA targets. SKYSEQ™ dramatically accelerates the identification of compounds with selective activity, enabling more efficient optimization of lead candidates.

  • ✓ Simultaneous screening of dozens of high-value RNA targets
  • ✓ Dramatically reduces time-to-lead identification
  • ✓ Enables selectivity profiling across the RNA target landscape
  • ✓ Integrated with SKYSTAR® and SKYLIBRARY™ for end-to-end discovery
SKYSEQ™

SKYAI™

SKYAI™ is Skyhawk's suite of machine learning tools, trained on the rich dataset generated by SKYSTAR®, SKYLIBRARY™, and SKYSEQ™. It integrates medicinal chemistry, animal studies, toxicology data, and clinical program results to continuously improve compound design and target prediction.

  • ✓ Trained on proprietary RNA-small molecule interaction data
  • ✓ Integrates med chem, animal studies, tox, and clinical data
  • ✓ Accelerates hit identification and lead optimization
  • ✓ Continuously refined by experimental and clinical feedback
SKYAI™